New injection for ulcerative colitis shows early promise, but trial halted
NCT ID NCT06681389
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested an injectable drug called NP-201 acetate in healthy volunteers and people with mild-to-moderate ulcerative colitis. The goal was to check safety, how the body processes the drug, and early signs of effectiveness. The trial was terminated early, so only limited safety and drug-level data are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NP-201 acetate injection
- What this could lead to
- If successful, this could point toward a new injectable treatment option for mild-to-moderate ulcerative colitis.
- What could go wrong
- This was an early-phase trial (Phase 1b/2a) that was terminated, so results are limited. The small size (35 participants) and early stage mean it is far from proving any benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame high triglycerides?
- Ancient exercise may hold key to stronger muscles in aging adults
- First human tests begin for new drug DW4421
- New ulcerative colitis drug put through drug interaction test
- Plant-Powered study seeks to unlock gut health secrets
- New oximeter software put to the test in small study